A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Study acronym: PERSISTCRSwNP1
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Aug 31, 2026 to Sep 28, 2026
    • Eligibility criteria expanded, about 21 words
    • Secondary endpoints: details revised at 5 of 8 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
The aim of this study is to assess the efficacy and safety of GSK5784283 administered as add-on maintenance therapy to participants with CRSwNP.
Trial Details
NCT Number NCT07782970
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Nasal Polyps
Related terms Nasal Polyps, Paranasal Sinus Diseases
Enrollment 218 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov